This cohort study assesses the risk and incidence of preterm birth, pregnancy-associated hypertensive disorders, and other outcomes associated with an approved vaccine for respiratory syncytial virus administered during pregnancy.
JAMA Network Open published a clinical update in Research Highlights on 21 Apr 2026.
The item focuses on Sequential Surveillance of RSVpreF Vaccination Early in the Postapproval Period.
Review the original article for the full source wording and details.